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͵ plausible diagnostic markers and therapeutic target in the Wnt signaling pathway for early intervention in CCT.
Introduction
Chronic inflammation is associated with many cancers (1) . For example, patients with ulcerative colitis, a chronic inflammatory disease of the large bowel, are at substantially increased risk of developing a form of colorectal cancer (CRC) known as colitis-associated cancer (CAC) (2, 3) . Moreover, few tools are available for detecting the colitis-to-cancer transition that allows early diagnoses at more treatable stages. Although CAC is thought to involve mutational events, epigenetic modifications and influences from the microenvironment, the pathogenesis of CAC is unclear.
A gene frequently found to be mutated early in the adenoma-to-carcinoma sequence in sporadic CRC is Adenomatous Polyposis Coli (APC), a tumor suppressor, which is a negative regulator of Wnt (wingless)/ȕ-catenin signaling (4, 5) . APC is also found to be mutated at the germline level in familial adenomatous polyposis (FAP), an autosomal dominant colon disorder, which promotes the development of CRC (6) . APC is an important component of the destruction complex in the Wnt/ȕ-catenin signaling pathway, which includes glycogen synthase kinase 3ȕ (GSK3ȕ), axin 2, casein kinase 1Į (CK1Į) and ȕ-catenin.
In the absence of Wnt ligand, ȕ-catenin is located primarily at the cell membrane, along with a small, dynamic cytoplasmic pool, which is targeted for proteosomal degradation when bound to the destruction complex. In the presence of Wnt ligands, the destruction complex Ͷ undergoes dissociation, resulting in the stabilization and accumulation of free ȕ-catenin in the cytoplasm, and subsequent translocation into the nucleus. Following nuclear translocation, ȕ-catenin displaces transcriptional co-repressors, allowing direct binding to the transcription factor, T-cell factor (TCF)/Lymphocyte enhancer factor (LEF) and subsequent transcription of Wnttarget genes including axin2, LGR5, c-Myc, and cyclin D1 (4) . Indeed, activating mutations in any one of the components of the Wnt/ȕ-catenin signaling cascade results in constitutive activation of this pathway as observed in cases of sporadic CRC and FAP (4) . Furthermore, high Wnt/ȕ-catenin signaling in sporadic CRC cells has been demonstrated to mark the cancer stem cell (CSC) compartment (7) . Other roles for Wnt/ȕ-catenin signaling in the intestinal tract include maintenance of adult crypt structure and proliferation of intestinal epithelial progenitor cells (5, 8) .
The contribution of Wnt/ȕ-catenin signaling to the colitis-to-cancer transition is poorly understood. Initial mutational studies suggested that activation of Wnt/ȕ-catenin signaling in the colitis-to-cancer transition is much less frequent than in sporadic CRC, and occurs 'later' in the pathogenic cascade (9) . As discussed below, our findings suggest that Wnt/ȕ-catenin signaling may occur earlier and be more prevalent than previously thought. We and others reported that sporadic CRC is initiated by a rare population of crypt cells called colon cancer stem cells (CCSCs) (10) (11) (12) (13) . We showed that high aldehyde dehydrogenase (ALDH) expression marked the CCSCs and enriched the tumor-initiating cell (TIC) population (10) . We recently identified a similar ALDH high population in the normal-appearing, non-dysplastic colonic epithelium of UC patients (14) . These results suggested for the first time that CAC might have a CSC origin.
Because they have the capacity to initiate the colitis-dysplasia-cancer transition, we refer to these ͷ cells as precursor-CCSCs (pCCSCs). pCCSCs can be propagated in vivo as tumor xenografts and in vitro as non-adherent spheres. The success rate of generating spheres from ALDH high cells derived from non-dysplastic colitic colon is low, 5-13% (14) and similar to the incidence of CAC in the UC population, ~2-19% (2).
Our findings to date indicate that pCCSCs are a valuable experimental model with which to interrogate the colitis-to-cancer transition, especially when considering early, pre-neoplastic events (14) . In particular, use of this model could pave a path for the development of methods that could aid early disease diagnosis and targeted drug therapy, which together may prevent the progression from colitis to cancer. Although pCCSCs might be involved in the colitis-to-cancer transition (14) , mechanisms underlying this transformation are unknown. Because initiation of sporadic CRC has been associated with activating mutations in the Wnt/ȕ-catenin signaling pathway (15, 16) , and CCSCs exhibit high Wnt/ȕ-catenin signaling (7), we re-examined the role of Wnt/ȕ-catenin signaling in the colitis-to-cancer transition. We proposed the existence of a Wnt/ȕ-catenin -dependent CSC hierarchy that is operative 'early' in the pathogenesis of CAC.
We demonstrate that high Wnt/ȕ-catenin signaling enriches tumor initiation activity from pCCSCs to such a degree that recapitulation of the adenocarcinoma phenotype is possible from a single cell.
Materials and Methods

Human Subjects
Tissues from colitis patients and colon cancer patients were retrieved under pathologic supervision with Institutional Review Board approvals at the University of Florida and the University of Michigan. Normal colon tissues were obtained from a local organ procurement organization (Life Quest; Gainesville, Florida).
Animals
Inbred NOD-SCID mice (5-6 weeks old) were used. Mice were maintained under pathogen-free conditions. Experiments were approved by the University of Florida Institutional Animal Care Committee.
Cell Culture
ALDH high sphere isolates were obtained from UC and CRC patients. The former are pCCSC; the latter are CCSC. The sphere isolates used in the study are CT-1, CT-2 and CA. CT-1 and CT-2 are two colitis sphere isolates (pCCSCs) obtained from two different colitic patients, CT-1 suffered from colitis for 8 years and CT-2 for 3 years. CA is a cancer sphere isolate (CCSC) obtained from a sporadic CRC patient. Isolated cells were cultured in serum-free media as previously described by Carpentino et al (14) . Serum-free media is referred to as defined media.
In vitro limiting dilution assay (clonogenic potential)
Cells with high or low eGFP intensities were deposited at 1, 
Statistical analysis
Data are presented as means + standard error as indicated in the figure legends. Statistical significance was defined as p < 0.05 determined by an unpaired Student's t-test or a one-way analysis of variance. To compare tumor growth rates, a mixed linear model was used with tumor volume as the response variable and with time and group as explanatory variables. We included subject (mouse) as a random effect, and we assumed a compound symmetric covariance structure. 
Results
Increased activation of Wnt/ȕ-catenin signaling in ALDH + pCCSCs in colitis
To determine the functional importance of Wnt/ȕ-catenin signaling in the colitis-to-cancer transition, we did immunohistochemistry to detect the presence of nuclear/cytoplasmic ȕ-catenin and ALDH in colonic tissues from healthy controls, UC patients, and sporadic CRC patients.
Patient characteristics for these tissues are in Supplementary Table 1 . Active Wnt/ȕ-catenin signaling was detected by nuclear/cytoplasmic ȕ-catenin staining ( Supplementary Fig. S1A ).
There were significantly more Wnt/ȕ-catenin pathway active cells in colitis (2. Our immunostaining data thus suggest an 'early' role for activation of Wnt/ȕ-catenin signaling in the colitis-to-cancer transition.
Generation and validation of a reporter construct specific for Wnt/ -catenin signaling
To ascertain the functional importance of Wnt/ -catenin signaling activity in pCCSCs during the colitis-to-cancer transition, we used a lentiviral dual fusion Wnt reporter, TTLG ͳͲ (consisting of 6x TCF/LEF binding sites and a minimal thymidine kinase promoter regulating firefly luciferase and eGFP reporter genes) ( Fig. 2A) . TTLG was transduced into pCCSCs (CT-1 and CT-2) as well as into CCSCs (CA) derived, respectively, from UC and sporadic CRC patients. CCSCs were operationally defined as ALDH high cells derived from CRC tissues that have demonstrated the ability to undergo serial passaging through immunocompromised mice with limited cell numbers while retaining the ability to recapitulate the primary tumor (10).
CCSCs served as a control for pCCSCs throughout the study, since CCSCs with high Wnt/ -catenin signaling have been demonstrated to display cancer stem cell properties (7). pCCSCs were operationally defined as ALDH high cells derived from colitic colon that (i) were isolated from nondysplastic UC colon, (ii) could be serially passaged through immunocompromised mice, and (iii) developed, first an anaplastic phenotype, and on serial passage transformed into a poorly differentiated adenocarcinoma (14) . TTLG specificity was verified by comparing the expression of Wnt target genes (Fig. 2B, Supplementary Fig. S3A Fig. S4B-C) . In addition, the resulting ALDH high -Wnt low primary xenograft tumors phenocopied the histological appearance of ALDH high -Wnt high primary xenograft tumors (Fig. 3D ) demonstrating a poorly differentiated adenocarcinoma phenotype.
Since tumor initiation is a property of both progenitor cells and stem cells (SC), we serially passaged these primary xenograft tumors based on two extreme levels of Wnt-activity to further 
ͳʹ distinguish these two populations. Similar to CSCs, CCSCs retain the ability to both initiate tumors on serial passaging and to undergo self-renewal.
Wnt/ȕ-catenin signaling has been implicated in the self-renewal of adult colon SCs and CCSCs (17, 18) . To demonstrate this phenomenon and also to enrich for stem-like cells in pCCSCs, secondary and tertiary tumors were generated from the 10% highest and lowest fluorescent cells derived from primary ALDH high -Wnt high xenograft tumor (S1A). Simultaneously, an in vitro LDA was performed to determine clonogenicity ( Supplementary Fig. S2B ). Fig. 5B and 3D) . Furthermore, besides the differential ȕ-catenin expression, the tumor revealed rare cells with expression of the goblet cell marker Muc2, thus confirming tumor heterogeneity (Fig. 5C ). These results confirm the greater level of CCSC enrichment bestowed by high Wnt-activity on ALDH high cells.
Inhibition of sustained Wnt-activity in CT-2 Wnt high -pCCSCs (ALDH high sphere cells) reduces tumor growth rates
To ascertain if high levels of sustained Wnt-activity are necessary for tumor-initiation and growth in CAC, we used an RNA interference approach in which we inhibited -catenin using two shRNAs, #1 and #2 (19) . A scrambled (Sc) shRNA was used as a control. Following lentiviral transduction and drug selection, the efficacy of the knockdown was confirmed by FACS. eGFP levels as a measure active Wnt/ -catenin signaling was reduced for both shRNA, with shRNA #1 showing the greatest reduction, compared the Sc shRNA for Wnt high -pCCSCs ( Supplementary Fig. S7A ). These results were confirmed by western blotting analysis to detect -catenin protein (Fig. 6A) . In vivo studies were done with shRNA #2 transduced into the Wnt high -pCCSC cell population. Tumors derived from shRNA #2 transduced Wnt high -pCCSCs and -CCSCs grew at a significantly slower rate compared to Sc transduced Wnt high -pCCSC and -ͳͶ CCSC derived tumors (Fig. 6B, Supplementary Fig. S7B ). Furthermore, we used a non-steroidal anti-inflammatory drug (NSAID), indomethacin, to attenuate Wnt/ -catenin signaling in Wnt highpCCSCs by suppressing -catenin expression (20, 21) . Wnt high -pCCSC tumors in vehicle-treated mice grew significantly faster than in indomethacin treated animals. The decreased Wnt-activity in tumors from mice treated with indomethacin was confirmed by immunostaining for -catenin (Fig. 6C ). This suggests a definitive role for high-level Wnt signaling in determining the rate at which colitis progresses towards CAC. Thus, therapeutic targeting of Wnt/ -catenin signaling may abrogate the progression of colitis to cancer.
Discussion
In the present study, we demonstrated early activation of Wnt/ -catenin signaling in the colitis-to-cancer transition based on immunohistochemical analysis as well as on in vitro and in vivo functional assays. Our initial immunohistochemical studies demonstrated that colitic epithelial cells may exhibit tumor-initiating activity based on their expression of ALDH along with an elevated co-expression of nuclear/cytoplasmic -catenin ( Fig. 1A and B) . We confirmed an association of high levels of Wnt/ -catenin signaling with self-renewal, sustained tumorinitiation and tumor heterogeneity, the three properties of CSCs. Moreover, we showed the importance of high Wnt activity as an additional enrichment marker of pCCSCs within the ALDH high population that promotes the progression from colitis to cancer.
ͳͷ Initial reports suggested that the Wnt/ -catenin signaling was activated late during disease pathogenesis (22) (23) (24) . However, more recent studies reported early Wnt/ -catenin pathway activation (25, 26) similar to that observed in colorectal cancer (27) . Moreover, the conclusions of the initial reports were mainly based on mutational analysis of Wnt signaling pathway components, while recent findings (including our own) suggesting early Wnt/ -catenin pathway activation are based on immunohistochemical data. To further examine this finding, we generated a Wnt/ -catenin reporter, which was validated by immunostaining to detect active β-catenin and real-time qPCR for representative Wnt/ -catenin pathway target genes. We observed a consistently higher expression level of all Wnt/ -catenin pathway target genes except for cMyc in CCSCs, which was consistent with the results of Vermeulen et al (7) . We speculate that the decrease in expression of some Wnt/ -catenin pathway target genes in the Wnt high population (Fig. 2B, S3A ) could be a result of CpG island methylation as reported by de Sousa E Melo et al in CRC (28) . Fig. S8 ). In this study, samples consisted of 2 colitis sphere isolates (pCCSCs) obtained from two individual colitic patients. This small sample size is due to the low percentage of colitic colons harboring pCCSCs, and attests to the difficulty of propagating these cells both in vivo and in vitro, which reflects the infrequently occurring transitions of colitis-to-cancer. In contrast, using the exact same methodology, our ability to propagate frank sporadic colon cancer as a tumor was nearly 90%, with a frequency of in vitro sphere formation of 50-60%. We also tested whether high Wnt-activity could be used as a therapeutic target to mitigate the colitis-to-cancer transition. To this end, we knocked down -catenin levels using an RNAi strategy to reduce Wnt-activity. Knockdown by shRNA #1 was so effective that the transduced cells did not survive more than a week in culture, likely owing to role of Wnt/ -catenin pathway in survival (38) . We observed a reduction in tumorigenicity of Wnt high -pCCSCs, followingcatenin knockdown (shRNA #2; Fig. 6B ), which was further confirmed by pharmacological ͳͺ inhibition of -catenin using indomethacin, an NSAID. Previously, indomethacin was used as pharmacotherapy for treating UC. Though this drug is no longer used to treat UC (39) (40) (41) , our study indicates the potential benefits of Wnt inhibition using pharmacological agents in attenuating the colitis-to-cancer transition.
Currently, there exists no direct evidence of a genetic cause for the increased risk of CRC in patients with UC. However, several molecular consequences such as generation of reactive oxygen species, microsatellite instability, telomere shortening and chromosomal instability have been attributed to inflammationdriven genomic stress that leads to CRC (42) . Though these studies have shed light on our understanding of inflammation-associated carcinogenesis, these markers lack sensitivity or specificity to be used as reliable biomarkers with which to assess the risk of CRC in patients with UC (42) (43) (44) (45) (46) 
